博濟醫藥(300404.SZ):酒石酸美託洛爾片獲得藥品註冊證書並將該藥品上市許可人100%的權益進行技術轉讓
格隆匯12月9日丨博濟醫藥(300404.SZ)公佈,公司控股子公司科技園公司收到國家藥品監督管理局核准簽發的《藥品註冊證書》,同時,科技園公司將該藥品上市許可人100%的權益進行技術轉讓。
藥品名稱:酒石酸美託洛爾片。酒石酸美託洛爾片主要用於治療高血壓、心絞痛、心肌梗死、肥厚型心肌病、主動脈夾層、心律失常、甲狀腺功能亢進、心臟神經官能症等。
該《藥品註冊證書》是科技園公司正式投入運營後獲得的首個藥品註冊證書,證明科技園公司質量體系符合中國GMP要求,對科技園公司CDMO業務具有里程碑式的意義。本次簽署《技術轉讓合同》,將對公司未來業績產生積極的影響,公司藥品研究、藥品生產相關業務部門將積極配合,完成該項目的技術轉讓工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.